|  | Webinar: 2021 Apollo Healthcare Predictions Thursday, February 4, 2021 | 1pm ET / 10am PT With so much disruption from COVID-19, this year’s global insights will provide a unique window into the minds of those professionals perhaps most tested by 2020 and their hopes and perspectives for 2021. Register Now! |
Featured Story | By Nick Paul Taylor Novartis has invested in Credence MedSystems to support the development and scale-up of its drug delivery systems. Credence will use the money to advance an injectable system designed to improve the user experience and fit into existing biopharma processes. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor A phase 2 clinical trial has provided further evidence of the tolerability benefits of giving bortezomib subcutaneously rather than intravenously. The evidence comes from a multiple myeloma trial that tested the proteasome inhibitor in combination with histone deacetylase inhibitor Farydak. read more By Nick Paul Taylor SinuSys has partnered with Pressure BioSciences to improve the delivery of steroids to the sinuses of patients recovering from surgical treatment of chronic sinusitis. The collaborators will use PBI’s nano-emulsification platform to optimize steroid delivery and minimize the risk of overdose. read more By Nick Paul Taylor The FDA has accepted a filing for approval of Impel NeuroPharma’s INP104 for the acute treatment of migraine. If approved, INP104 will become the first commercial product based on Impel’s technology for delivering therapeutics to the upper nasal space. read more By Angus Liu More than a year after an FDA rebuff, GlaxoSmithKline’s ViiV Healthcare has finally won U.S. clearance for an injectable drug that could relieve HIV patients of the trouble of taking daily pills. The FDA today greenlighted Cabenuva, the world’s first complete long-acting, injectable HIV regimen. read more By Phil Taylor While big companies can shrug off a failure, the wasted investment and missed commercial opportunities can still be damaging. For smaller companies, flunking a trial can jeopardize the future of the business. read more Resources Sponsored By: Polpharma Biologics Innovative cell lines and early process development are critical to generate a high producing cell lines alongside a USP strategy to meet high quality standards. Sponsored By: Blue Matter Biopharma companies in rare diseases: How to maximize the odds of success by becoming a valued member of the unique “rare disease ecosystem.” Sponsored by: Covance Download the whitepaper to learn how your safety organization can implement automation technologies to enable process and cost efficiencies, improve resource allocation and ensure compliance and quality. Sponsored by: Rousselot This infographic describes the benefits of GelMA in various biomedical applications and how X-Pure® GelMA can help you in your developments. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Learn about proven strategies for a successful product launch, including cross-functional team collaboration, risk management and using the right project management tools. Sponsored by: Catalent This eBook provides insights on key approaches and considerations for preparing your drug development program for long-term success. Sponsored by: Catalent In this webinar, pharmaceutical scientists present real-life examples of challenges they’ve overcome in the transfer of oral small molecules from a dedicated early-phase development site to a dedicated late-phase manufacturing site. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. | 
